HIGHLIGHTS
- who: Harjeet Singh et al. from the United Kingdom University of Southampton have published the paper: Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies, in the Journal: (JOURNAL)
- what: The aims were to determine the safety profile and maximum tolerated dose (MTD) of SB CAR T-cells. The authors report on the long-term findings of non-viral, SB generated, autologous CD19 directed CAR T-cells in patients with advanced lymphoid malignancies. The intent of this trial was to investigate whether modifications to the CAR T product would increase . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.